Just – Evotec Biologics receives grant for COVID-19 monoclonal antibody optimisation and cell line development from the COVID-19 therapeutics accelerator Grant enables the optimisation of…
Just – Evotec Biologics to provide process development and manufacturing of monoclonal antibody
Just – Evotec Biologics to provide process development required for phase I cGMP clinical manufacturing of broadly neutralising antibody against HIV
Partnership is part of a contract awarded to Ology Bioservices by the Department of Defense to develop and manufacture monoclonal antibodies for treatment and prevention…
Just – Evotec Biologics will apply its fully integrated technology platform in order to accelerate Oncoresponse’s lead product candidate through development and into the clinic
The J.POD® technology expands Evotec’s capabilities into flexible commercial biologics manufacturing Confirms Evotec’s role as leading external innovator for the integrated outsourcing of drug discovery…
• MSD to gain access to manufacturing know-how within Just – Evotec Biologics’ J.POD® facility (“Facility of the future”) • Multi-year collaboration in form of…
Biocon Biologics in-licenses an early-stage biosimilar asset, will undertake development, manufacturing and commercialisation under its own label. Just – Evotec Biologics has received a license…
Acquisition extends Evotec’s multimodality offering, with integrated solutions for small molecules and biologics. Expands Evotec’s US footprint in Seattle and machine learning capabilities. Deal value…
Just Biotherapeutics, Inc. (“Just.Bio”), an integrated design company focused on technologies for accelerating the development and manufacture of biotherapeutics, announced today that they have entered…
Evotec’s offering of integrated solutions extended to biologics. Addition of longstanding biologics expertise based on key talents, innovative ML (machine learning) driven technologies and sophisticated…